Royalty Pharma RPRX
$68.45 +$0.73 (+1.08%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $67.91 -0.79%
Open$68.17
Prev close$67.72
Day range$67.95 – $68.83
Volume3.53M
Market cap$30.48B
P/E (TTM)44.7
Dividend yield1.35%
RPRX Stock News
Headlines matching Royalty Pharma or the RPRX ticker, most recent first.
- Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $70
- TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $68 Positive
- UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66
- Royalty Pharma(RPRX.US) Officer Sells US$5.85 Million in Common Stock
- BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Announces Target Price $63
- Form 144 | Royalty Pharma(RPRX.US) Officer Proposes to Sell 5.85 Million in Common Stocks
- Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66 Positive
- Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $65
- Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65 Positive
- Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $70 Positive
- UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66 Positive
- J.P. Morgan Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $62 Positive
- Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66
- TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65 Positive
- BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating
No comments yet — be the first to weigh in on RPRX.
Sign in to join the discussion.